Journal Mobile Options
Table of Contents
Vol. 121, No. 4, 2000
Issue release date: April 2000

Allergy and the Gut

Bischoff S.C. · Mayer J.H. · Manns M.P.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

There have frequently been doubts as to the relevance of food allergy, in particular as far as the involvement of the intestinal tract is concerned. Several studies, however, have confirmed the existence of allergic reactions in the gut, with an estimated prevalence of about 1–2% in adults. Clinical symptoms are unspecific and include nausea, vomiting, abdominal pain, cramping and diarrhea. Intestinal mast cells, as well as intestinal eosinophils, have been shown to be involved in the pathogenesis of food-allergy-related enteropathy. In addition to classical IgE-dependent degranulation, further agonists have been demonstrated for mast cell activation, for example IL-4. The methods used to confirm the diagnosis of instestinal allergy are still insufficient. Until now, blinded oral challenge procedures with food antigens have been accepted as the ‘gold standard’ in diagnosing food allergy, although these tests have practical problems. Therefore, new test systems have been developed, such as endoscopic provocation tests, that may improve diagnostic procedures. Elimination diet still presents the main basis of therapy. Aspects to be focused on in the future are the role fo IgE-independent allergic mechanisms in intestinal allergy, the impact of cross-reactivity with other allergens and the relationship to other inflammatory bowel diseases such as Crohn’s disease, ulcerative colitis, celiac disease and irritable bowel syndrome.

Copyright © 2000 S. Karger AG, Basel



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Finn R: Food allergy – fact or fiction: A review. J R Soc Med 1992;85:560–564.
  2. Bischoff SC, Herrmann A, Manns MP: Prevalence of adverse reactions to food in patients with gastrointestinal disease. Allergy 1996;51:811–818.

    External Resources

  3. Sampson HA: Food allergy. Part 1: Immunopathogenesis and clinical disorders. J Allergy Clin Immunol 1999;103:717–728.
  4. Jones VA, Dickinson RJ, Workman E, Wilson AJ, Freeman AH, Hunter JO: Crohn’s disease: Maintenance of remission by diet. Lancet 1985;ii:177–180.
  5. Ballegaard M, Bjergstrom A, Bronndum S, Hylander E, Jensen L: Self-reported food intolerance in chronic inflammatory bowel disease. Scand J Gastroenterol 1997;32:569–571.
  6. Zwetschenbaum JF, Burakoff R: Food allergy and the irritable bowel syndrome. Am J Gastroenterol 1988;83:901–904.
  7. Young E, Stoneham MD, Petruckevitch A, Barton J, Rona R: A population study of food intolerance. Lancet 1994;343:1127–1130.
  8. Kristjansson I, Ardal B, Jonsson JS, Sirudsson JA, Foldevi M, Bjorksten B: Adverse reaction to food and food allergy in young children in Iceland and Sweden. Scand J Prim Health Care 1999;17:30–34.

    External Resources

  9. Bock SA: Prospective appraisal of complaints of adverse reactions to foods in children during the first 3 years of life. Pediatrics 1987;79:683–688.
  10. Host A, Halken S: A prospective study of cow milk allergy in Danish infants during the first 3 years of life. Clinical course in relation to clinical and immunological type of hypersensitivity reaction. Allergy 1990;45:587–596.
  11. Bishop JM, Hill DJ, Hosking CS: Natural history of cow milk allergy: Clinical outcome. J Pediatr 1990;116:862–867.
  12. Bischoff SC: Mucosal allergy: Role of mast cells and eosinophil granulocytes in the gut. Baillière’s Clin Gastroenterol 1996;10:443–459.
  13. Bruijnzeel-Koomen C, Ortolani C, Aas K, Bindslev-Jensen C, Björkstén B, Moneret-Vautrin D, Wüthrich B: Adverse reactions to food. Allergy 1995;50:623–635.
  14. Bischoff SC, Mayer J, Wedemeyer J, Meier PN, Zeck-Kapp G, Wedi B, Kapp A, Cetin Y, Gebel M, Manns MP: Colonoscopic allergen provocation (COLAP): A new diagnostic approach for gastrointestinal food allergy. Gut 1997;40:745–753.
  15. Bischoff SC, Mayer J, Meier PN, Zeck-Kapp G, Manns MP: Clinical significance of the colonoscopic allergen provocation test. Int Arch Allergy Immunol 1997;113:348–351.
  16. Podolsky D: Inflammatory bowel disease. Part 1. N Engl J Med 1991;325:928–937.
  17. Podolsky D: Inflammatory bowel disease. Part 2. N Engl J Med 1991;325:1008–1018.
  18. Hed J: Coeliac disease: A food allergy? Monogr Allergy. Basel, Karger, 1996, vol 32, pp 204–210.
  19. Talley NJ, Shorter RG, Phillips SF, Zinsmeister AR: Eosinophilic gastroenteritis: A clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues. Gut 1990;31:54–58.
  20. Naylor AR: Eosinophilic gastroenteritis. Scott Med J 1990;35:163–165.
  21. Ebner C, Hirschwehr R, Bauer L, Breiteneder H, Valenta R, Ebner H, Kraft D, Scheiner O: Identification of allergens in fruits and vegetables: IgE cross-reactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin). J Allergy Clin Immunol 1995;95:962–969.
  22. Fritsch R, Bohle B, Vollmann U, Wiedermann U, Jahn-Schmid B, Krebitz M, Breiteneder H, Kraft D, Ebner C: Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cells. J Allergy Clin Immunol 1998;102:679–686.
  23. Valenta R, Duchene M, Ebner C, Valent P, Silaber C, Deviller P, et al: Profilins constitute a novel family of functional plant pan-allergens. J Exp Med 1992;175:377–385.
  24. Vrtala S, Hirtenlehner K, Susani M, Hufnagl P, Binder BR, Vangelista L, Pastore A, Sperr WR, Valent P, Ebner C, Kraft D, Valenta R: Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: Candidates for specific immunotherapy. Int Arch Allergy Immunol 1999;118:218–219.
  25. Crowe SE, Perdue MH: Gastrointestinal food hypersensitivity: Basic mechanisms of pathophysiology. Gastroenterology 1992;103:1075–1095.
  26. Bischoff SC, Dahinden CA: c-kit ligand: A unique potentiator of mediator release by human lung mast cells. J Exp Med 1992;175:237–244.
  27. Galli SJ, Tsai M, Wershil BK: The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am J Pathol 1993:142:965–974.
  28. Bischoff SC, Dahinden CA: Effect of c-kit ligand on mediator release by human lung mast cells. Int Arch Allergy Immunol 1992;99:319–322.
  29. Bischoff SC, Schwengberg S, Wordelmann K, Weimann A, Raab R, Manns MP: Effect of c-kit ligand, stem cell factor, on mediator release by human intestinal mast cells isolated from patients with inflammatory bowel disease and controls. Gut 1996;38:104–114.
  30. Bischoff SC, Schwengberg S, Raab R, Manns MP: Functional properties of human intestinal mast cells cultured in a new culture system. Enhancement of IgE receptor-dependent mediator release and response to stem cell factor. J Immunol 1997;159:5560–5567.

    External Resources

  31. Valent P, Besmer J, Sillaber CH, Butterfield JH, Eher R, Majdic O, Kishi K, Kleptko W, Eckersberger F, Kaltenrunner R, Lechner K, Bettelheim P: Failure to detect IL-3 binding sites on human mast cells. J Immunol 1990;145:3432–3437.

    External Resources

  32. Bischoff SC, Sellge A, Lorentz A, Sebald W, Raab R, Manns MP: Interleukin-4 enhances proliferation and mediator release in mature human mast cells. Proc Natl Acad Sci USA 1999;96:8080–8085.
  33. Brunner T, Heusser CH, Dahinden CA: Human peripheral blood basophils primed by interleukin 3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation. J Exp Med 1993;177:605–611.
  34. Dvorak AM, Monahan RA, Osage JE, Dickersin GR: Mast-cell degranulation in Crohn’s disease. Lancet 1978;i:498.
  35. Strobel S, Busuttil A, Ferguson A: Human intestinal mucosal mast cells: Expanded population in untreated coeliac disease. Gut 1983;24:222–227.

    External Resources

  36. Patrick MK, Dunn IJ, Buret A, Miller HRP, Huntley JF, Gibson S, Gall DG: Mast cell protease release and mucosal ultrastructure during intestinal anaphylaxis in the rat. Gastroenterology 1988;94:1–9.

    External Resources

  37. Reimann HJ, Lewin J: Gastric mucosal reactions in patients with food allergy. Am J Gastroenterol 1988;11:1212–1219.
  38. Bagnato GF, Di Cesare E, Caruso RA, Gulli S, Cugliari A, Morabito Lo Prete A, Previti M, Muscara M, Bottari M: Gastric mucosal mast cells in atopic subjects. Allergy 1995;50:322–327.
  39. D’Inca R, Ramage JK, Hunt RH, Perdue MH: Antigen-induced mucosal damage and restitution in the small intestine of the immunized rat. Int Arch Allergy Appl Immunol 1990;91:270–277.
  40. Gordon JR, Burd PR, Galli SJ: Mast cells as a source of multifunctional cytokines. Immunol Today 1990;11:458–464.
  41. Echtenacher B, Männel DN, Hultner L: Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996;381:75–77.
  42. Malaviya R, Ikeda T, Ross E, Abraham SN: Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 1996;381:77–80.
  43. Bischoff SC, Lorentz A, Schwengberg S, Weier G, Raab R, Manns MP: Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Gut 1999;44:643–652.
  44. Lorentz A, Schwengberg S, Mierke C, Manns MP, Bischoff SC: Human intestinal mast cells produce IL-5 in vitro upon IgE receptor cross-linking and in vivo in the course of intestinal inflammatory disease. Eur J Immunol 1999;29:1496–1503.
  45. Lorentz A, Schwengberg S, Sellge G, Manns MP, Bischoff SC: Human intestinal mast cells are capable of producing different cytokine profiles: Role of IgE receptor cross-linking and IL-4. J Immunol 2000;164:43–48.

    External Resources

  46. Miyajima I, Dombrowicz D, Martin TR, Ravetch JV, Kinet JP, Galli SJ: Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and FcγRIII. J Clin Invest 1997;99:901–914.
  47. Iikura M, Takaishi T, Hirai K, Yamada H, Iida M, Koshino T, Morita Y: Exogenous nitric oxide regulates the degranulation of human basophils and rat peritoneal mast cells. Int Arch Allergy Immunol 1998;115:129–136.
  48. Joos GF, Lefebre RA, Bullock GR, Pauwels RA: Role of 5-hydroxytryptamine and mast cells in the tachykinin-induced contraction of rat trachea in vitro. Eur J Pharmacol 1997;338:259–268.
  49. Suzuki R, Furuno T, McKay DM, Wolvers D, Teshima R, Nakanishi M, Bienenstock J: Direct neurite-mast cell communication in vitro occurs via the neuropeptide substance P. J Immunol 1999;163:2410–2415.
  50. Bonini S, Lambiase A, Bonini S, Angelucci F, Magrini L, Manni L, Aloe L: Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma. Proc Natl Acad Sci USA 1996;93:10955–10960.
  51. Marshall JS, Gomi K, Blennerhassett MG, Bienenstock J: Nerve growth factor modifies the expression of inflammatory cytokines by mast cells via a prostanoid-dependent mechanism. J Immunol 1999;167:4271–4276.
  52. Nilsson G, Forsberg-Nilsson K, Xiang Z, Hallbook F, Nilsson K, Metcalfe DD: Human mast cells express functional TrkA and are a source of nerve growth factor. Eur J Immunol 1997;27:2295–2301.
  53. Castagliuolo I, Wang CC, Valenick L, Pasha A, Nikulasson S, Carraway RE, Pothoulakis C: Neurotensin is a proinflammatory neuropeptide in colonic inflammation. J Clin Invest 1999;103:843–849.

    External Resources

  54. Furuta GT, Ackerman SJ, Wershil BK: The role of the eosinophil in gastrointestinal diseases. Curr Opin Gastroenterol 1995;11:541–547.
  55. Levy AM, Kita K: The eosinophil in gut inflammation: Effector or director? Gastroenterology 1996;110:952–954.
  56. Dvorak AM: Ultrastructural evidence for release of major basic protein-containing crystalline cores of eosinophil granules in vivo: Cytotoxic potential in Crohn’s disease. J Immunol 1980;125:460–462.

    External Resources

  57. Raab Y, Fredens K, Gerdin B, Hällgren R: Eosinophil activation in ulcerative colitis. Dig Dis Sci 1998;43:1061–1070.
  58. Levy AM, Gleich GJ, Sandborn WJ, Tremaine WJ, Steiner ML, Phillips SF: Increased eosinophil granule proteins in gut lavage fluid from patients with inflammatory bowel disease. Mayo Clin Proc 1997;72:117–123.
  59. Bischoff SC, Grabowsky J, Manns MP: Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls. Dig Dis Sci 1997;42:394–403.
  60. Bischoff SC, Mayer JH, Nguyen Q-T, Stolte M, Manns MP: Immunohistochemical assessment of intestinal eosinophil activation in patients with eosinophilic gastroenteritis and inflammatory bowel disease. Am J Gastroenterol 1999;94:3521–3529.
  61. Berstad A, Borkje B, Riedel B, Elsayed S, Berstad A: Increased fecal eosinophil cationic protein in inflammatory bowel disease. Hepatogastroenterology 1993;40:276–278.
  62. Rothenberg ME: Eosinophilia. N Engl J Med 1998;338:1592–1600.
  63. Kosa L, Kereki E, Borzsonyl L: Copro-eosinophil cationic protein (ECP) in food allergy. Allergy 1996;51:964–966.
  64. Bengtsson U, Knutson TW, Knutson L, Dannaeus A, Hällgren R, Ahlstedt S: Eosinophil cationic protein and histamine after intestinal challenge in patients with cow’s milk intolerance. J Allergy Clin Immunol 1997;100:216–221.
  65. Raible DG, Schulman ES, DiMuzio J, Cardillo R, Post TJ: Mast cell mediators prostaglandin-D2 and histamine activate human eosinophils. J Immunol 1992;148:3536–3542.

    External Resources

  66. Gounni AS, Lamkhioued B, Delaporte E, Dubost A, Kinet JP, Capron A, Capron M: The high-affinity IgE receptor on eosinophils: From allergy to parasites or from parasites to allergy? J Allergy Clin Immunol 1994;94:1214–1216.

    External Resources

  67. Capron M, Gounni SA, Morita M, Truong MJ, Prin L, Kinet JP, Capron A: Eosinophils: From low- to high-affinity immunoglobulin E receptors. Allergy 1995;50(suppl 25):20–23.
  68. Bischoff SC, Brunner T, de Weck AL, Dahinden CA: Interleukin 5 modifies histamine release and leukotriene generation by human basophils in response to diverse agonists. J Exp Med 1990;172:1577–1582.
  69. Bischoff SC, de Weck AL, Dahinden CA: Interleukin 3 and granulocyte/macrophage-colony-stimulating factor render human basophils responsive to low concentrations of complement component C3a. Proc Natl Acad Sci USA 1990:87:6813–6817.
  70. Takafuji S, Bischoff SC, de Weck AL, Dahinden CA: IL-3 and IL-5 prime normal human eosinophils to produce leukotriene C4 in response to soluble agonists. J Immunol 1991:147:3855–3861.
  71. Takafuji S, Bischoff SC, de Weck AL, Dahinden CA: Opposing effects of tumor necrosis factor-alpha and nerve growth factor upon leukotriene C4 production by human eosinophils triggered with N-formyl-methionyl-leucyl-phenylalanine. Eur J Immunol 1992;22:969–974.
  72. Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA: RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med 1992;176:1489–1495.
  73. Bischoff SC, Krieger M, Brunner T, Rot A, von Tscharner V, Baggiolini M, Dahinden CA: RANTES and related chemokines activate human basophil granulocytes through different G protein-coupled receptors. Eur J Immunol 1993;23:761–767.

    External Resources

  74. Baggiolini M, Dahinden CA: CC chemokines in allergic inflammation. Immunol Today 1994;15:127–133.
  75. Alam R, Grant JA: The chemokines and the histamine-releasing factors: Modulation of function of basophils, mast cells and eosinophils. Chem Immunol 1995;61:148–160.
  76. Rollins BJ: Chemokines. Blood 1997;90:909–928.
  77. Sallusto F, Lanzavecchia A, Mackay CR: Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998;19:568–574.
  78. Kay AB, Ying S, Varney V, Gaga M, Durham SR, Moqbel R, Wardlaw AJ, Hamind Q: Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5 and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med 1991;173:775–778.
  79. Kolmannskog S, Haneberg B: Immunoglobin E in feces from children with allergy. Int Arch Allergy Appl Immunol 1985;76:133–137.

    External Resources

  80. Sampson HA: Food allergy. Part 2: Diagnosis and management. J Allergy Clin Immunol 1999;103:981–989.
  81. Bengtsson U, Nilsson-Balknäs U, Hanson LÅ, Ahlstedt S: Double blind, placebo controlled food reactions do not correlate to IgE allergy in the diagnosis of staple food related gastrointestinal symptoms. Gut 1996;39:130–135.
  82. Belut D, Moneret-Vautrin DA, Nicolas JP, Grilliat JP: IgE levels in intestinal juice. Dig Dis Sci 1980;25:323–332.

    External Resources

  83. Huggins KG, Brostoff J: Local production of specific IgE antibodies in allergic-rhinitis patients with negative skin tests. Lancet 1975;ii:148–150.
  84. Andre F, Andre C, Colin L, Cavagna S: IgE in stools as indicator of food sensitization. Allergy 1995;50:328–333.
  85. Sampson HA, Broadbent KR, Bernhisel-Broadbent J: Spontaneous release of histamine from basophils and histamine-releasing factor in patients with atopic dermatitis and food hypersensitivity. N Engl J Med 1989;321:228–232.
  86. Nolte H, Stahl-Skov P, Kruse A, Schiotz PO: Histamine release from dispersed human intestinal mast cells. A method using biopsies from children and adults. Allergy 1989;44:543–553.
  87. De Weck AL, Stadler BM, Urwyler A, Wehner HU, Bühlmann RP: Cellular allergen stimulation test (CAST) – a new dimension in allergy diagnostics. ACI News 1993;5:9–14.
  88. Rossi RE, Monasterolo G, Operti D: A comparative study of the tryptase release test and the cellular allergen stimulation test (CAST) in mite sensitive patients. Clin Exp Allergy 1998; 28:752–757.

    External Resources

  89. Raithel M, Matek M, Baenkler HW, Jorde W, Hahn EG: Mucosal histamine content and histamine secretion in Crohn’s disease, ulcerative colitis and allergic enteropathy. Int Arch Allergy Immunol 1995;108:127–133.
  90. van Neerven RJJ, Ebner C, Yssel H, Kapsenberg ML, Lamb JR: T-cell responses to allergens: Epitope-specificity and clinical relevance. Immunol Today 1996;17:526–532.

    External Resources

  91. Nicodemus C, Philip G, Jones N, Hirani S, Norman P: Integrated clinical experience with tolerogenic peptides. Int Arch Allergy Immunol 1997;113:326–328.

    External Resources

  92. Kon OM, Sihra BS, Barkans J, Compton CH, Barnes NC, Kay AB: In vivo effects of a PRIMATIZED® anti-CD4 monoclonal antibody, SB210396 (IDEC CE9.1), on CD4+ T lymphocytes in chronic severe asthma. J Allergy Clin Immunol 1998;101:S9.
  93. Corne J, Djukanovic R, Thomas L, Warner J, Botta L, Grandordy B, Gygax D, Heusser C, Patalano F, Richardson W, Kilchherr E, Staehelin T, Davis F, Gordon W, Sun L, Liou R, Wang G, Chang TW, Holgate S: The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety, and pharmacokinetics. J Clin Invest 1997;99:879–887.
  94. Garlisi CG, Kung TT, Wang P, Minnicozzi M, Umland SP, Chapman RW, Stelts D, Crawley Y, Falcone A, Myers JG, Jones H, Billah MM, Kreutner W, Egan RW: Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation. Am J Respir Cell Mol Biol 1999;20:248–255.
  95. Borish LC, Nelson HS, Lanz M, Claussen LR, Martin DW, Garrison L: Phase I/II study of interleukin-4 receptor (IL-4R) in moderate asthma. J Allergy Clin Immunol 1998;101:S8.
  96. Vercelli D, De Monte L, Monticelli S, Di Bartolo C, Agresti A: To E or not to E? Can an IL-4-induced B cell choose between IgE and IgG4? Int Arch Allergy Immunol 1998;116:1–4.
  97. Jenmalm MC, Bjorksten B, Macaubas C, Holt BJ, Smallacombe TB, Holt PG: Allergen-induced cytokine secretion in relation to atopic symptoms and immunoglobin E and immunoglobin G subclass antibody responses. Pediatr Allergy Immunol 1999;10:168–177.
  98. Barnes KC, Marsh DG: The genetics and complexity of allergy and asthma. Immunol Today 1998;19:325–332.
  99. Anderson GG, Morrison JFJ: Molecular biology and genetics of allergy and asthma. Arch Dis Child 1998;78:488–494.
  100. Thomas NS, Wilkinson J, Holgate ST: The candidate region approach to the genetics of asthma and allergy. Am J Respir Crit Care Med 1997;156:S144–151.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50